Development of intra-nasal flu vaccine effective against several
flu strains.
Overview
BiondVax's universal multi-season / multi-strain, intranasal flu
Click here to request more information, about this company (FOR COLLABORATION IN R&D. ONLY!)
Note - you have to be registered in this server to
request information. If you haven't done so
yet, please register in this server
Your requests will be forwarded to the developer, who
will contact you directly
You can also see the list of
documents you already requested more information about
vaccine is a result of intensive R&D efforts conducted by
Professor Ruth Arnon and her team at the Weizmann Institute,
since the early 80's. The vaccine introduces an innovative
scientific approach that has been validated in an advanced animal
model.
The Company's technology utilizes a combination of "conserved
epitopes" derived from the influenza virus possessing strong
immunogenic capabilities. The "conserved epitopes" are common to
the vast majority of flu virus strains regardless of their
antigenic drifts and shifts. The selected conserved epitopes
activate the human immune system in a long-lasting and effective
manner against known and future strains of the influenza virus.
